[go: up one dir, main page]

AR046036A1 - Composiciones de risedronato y metodos para su uso - Google Patents

Composiciones de risedronato y metodos para su uso

Info

Publication number
AR046036A1
AR046036A1 ARP040103537A ARP040103537A AR046036A1 AR 046036 A1 AR046036 A1 AR 046036A1 AR P040103537 A ARP040103537 A AR P040103537A AR P040103537 A ARP040103537 A AR P040103537A AR 046036 A1 AR046036 A1 AR 046036A1
Authority
AR
Argentina
Prior art keywords
risedronate
pharmaceutical composition
accordance
compositions
methods
Prior art date
Application number
ARP040103537A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Maurice Kent Gately
Jun Shi
David Ernest Burgio Jr
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34958880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR046036A1 publication Critical patent/AR046036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso de una composición farmacéutica para tratar o prevenir un trastorno óseo que contiene del 65 % al 110 % de la dosis efectiva acumulativa de risedronato que comprende administrar por vía oral al ser humano u otro mamífero de conformidad con un esquema de dosificación continua de uno, dos o tres días consecutivos al mes. Dicho uso en donde dicha composición farmacéutica se administra un día por mes en la forma de una dosis unitaria que comprende de 100 mg a 165 mg de risedronato, de preferencia 150 mg de risedronato. Dicho uso en donde el trastorno óseo es osteoporosis. Composición farmacéutica adecuada para administrarse de conformidad con dicho esquema de dosificación continua, dicha composición farmacéutica comprende: a) entre 65 % y 110 % de la dosis efectiva acumulativa de risedronato; y b) uno o más excipientes farmacéuticamente aceptables. Dicha composición farmacéutica en donde la forma de dosificación es una tableta.
ARP040103537A 2004-07-23 2004-09-29 Composiciones de risedronato y metodos para su uso AR046036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/897,897 US20050070504A1 (en) 2001-12-21 2004-07-23 Risedronate compositions and their methods of use

Publications (1)

Publication Number Publication Date
AR046036A1 true AR046036A1 (es) 2005-11-23

Family

ID=34958880

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103537A AR046036A1 (es) 2004-07-23 2004-09-29 Composiciones de risedronato y metodos para su uso

Country Status (20)

Country Link
US (1) US20050070504A1 (es)
EP (1) EP1776123A1 (es)
JP (3) JP5377852B2 (es)
KR (2) KR20080083219A (es)
CN (1) CN101146542A (es)
AR (1) AR046036A1 (es)
AU (2) AU2004322703B2 (es)
BR (1) BRPI0418973A (es)
CA (1) CA2564898A1 (es)
IL (1) IL180907A0 (es)
IS (1) IS8597A (es)
MA (1) MA28778B1 (es)
MX (1) MX2007000967A (es)
NO (1) NO20071058L (es)
NZ (1) NZ552799A (es)
PE (1) PE20060144A1 (es)
RU (1) RU2007103306A (es)
TW (1) TWI351286B (es)
WO (1) WO2006022755A1 (es)
ZA (1) ZA200701308B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
PT1506041E (pt) * 2002-05-10 2007-12-28 Hoffmann La Roche Ácido ibandrónico para o tratamento e a prevenção da osteoporose
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
AU2011218625B2 (en) * 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP3047847A1 (en) * 2005-10-12 2016-07-27 OPKO Renal, LLC Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
JP2011529901A (ja) * 2008-07-31 2011-12-15 味の素株式会社 リセドロネートまたはその塩の低投与量形態
KR101379664B1 (ko) * 2008-09-23 2014-04-02 한림제약(주) 리세드론산 또는 그의 염 및 비타민 ｄ를 포함하는 약학 조성물
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
CA1336328C (en) * 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
WO1994000130A1 (en) * 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Compositions for the treatment of arthritis containing phosphonates and nsaids
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
DE69826660T2 (de) * 1997-06-11 2005-10-06 The Procter & Gamble Company, Cincinnati Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) * 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6225801B1 (en) * 1999-01-14 2001-05-01 Lucent Technologies Inc. Article comprising electronic circuits and devices with magnetically programmable electrical resistance
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
NZ523086A (en) * 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
EP1458400A1 (en) * 2001-12-13 2004-09-22 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
PT1506041E (pt) * 2002-05-10 2007-12-28 Hoffmann La Roche Ácido ibandrónico para o tratamento e a prevenção da osteoporose
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
JP2015038135A (ja) 2015-02-26
IS8597A (is) 2007-01-24
MA28778B1 (fr) 2007-08-01
JP2013231087A (ja) 2013-11-14
JP5377852B2 (ja) 2013-12-25
MX2007000967A (es) 2007-07-11
US20050070504A1 (en) 2005-03-31
AU2011200905A1 (en) 2011-03-24
AU2004322703A1 (en) 2006-03-02
JP5910698B2 (ja) 2016-04-27
NO20071058L (no) 2007-02-22
ZA200701308B (en) 2008-07-30
BRPI0418973A (pt) 2007-12-04
RU2007103306A (ru) 2008-09-10
TWI351286B (en) 2011-11-01
CN101146542A (zh) 2008-03-19
NZ552799A (en) 2010-04-30
PE20060144A1 (es) 2006-04-17
KR20070038115A (ko) 2007-04-09
WO2006022755A1 (en) 2006-03-02
AU2004322703B2 (en) 2010-12-02
KR20080083219A (ko) 2008-09-16
JP5761274B2 (ja) 2015-08-12
EP1776123A1 (en) 2007-04-25
TW200603816A (en) 2006-02-01
CA2564898A1 (en) 2006-03-02
IL180907A0 (en) 2007-07-04
JP2008507513A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
TR200002207T1 (tr) Slekoksib bileşikleri.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
AR025938A1 (es) Nuevas composiciones farmaceuticas.
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
CY1112964T1 (el) Κιτ για φαρμακευτικη χρηση
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
ES2254046T1 (es) Tratamiento de hiperplasia prostatica benigna.
NO20080244L (no) Doseringsstyring for prasugrel
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
BR0012822A (pt) Formulação farmacêutica, e, forma de dosagem em tablete
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Legal Events

Date Code Title Description
FB Suspension of granting procedure